Samsung Electronics Becomes Largest Shareholder of U.S. Gene Analysis Equipment Firm Element Biosciences

Samsung Electronics has acquired the position of largest shareholder in the U.S.-based gene analysis equipment company, Element Biosciences (hereafter referred to as Element), by participating as a strategic investor.

On June 10 (Korean time), Samsung Electronics announced that it had made an additional equity investment of USD 175 million (approximately KRW 266.7 billion) in Element by participating in the company's Series E funding round. Previously, in July 2024, Samsung Electronics had also taken part in Element's Series D funding round.

Through this investment, Samsung Electronics has further strengthened its ability to secure core technologies in the rapidly growing global precision medicine market and reinforced its future growth engines. Building on Samsung Electronics' investment, Element plans to accelerate the commercialization of next-generation gene sequencing and multi-omics ecosystems, and to expand its product roadmap for large-scale global clinical and diagnostic applications.

Founded in 2017 in San Diego, United States, Element possesses 'DNA sequencing' technology that has dramatically reduced analysis costs while raising genome analysis accuracy to an industry-leading 99.99%.

DNA sequencing is a technology that reads the DNA base sequence—the blueprint of life—to identify genetic variations and characteristics. The genomic information obtained through this process is widely used in future precision medicine fields, including: ▲ understanding innate genetic traits and predicting diseases in advance ▲ early detection and monitoring of diseases based on genetic variations ▲ development of personalized treatment methods.

Samsung Electronics is focusing on Element's next-generation gene sequencing technology and multi-omics. Multi-omics is a technology that simultaneously analyzes not only DNA, but also various biological data such as RNA and proteins, which demonstrate how DNA actually functions. This enables more accurate identification of the root causes of diseases and the development of new drugs, making it a core technology for next-generation precision medicine.

Samsung Electronics plans to combine its artificial intelligence (AI) capabilities, medical devices, and digital health technologies with Element's DNA and multi-omics analysis technologies to secure new business opportunities, such as next-generation genetic diagnostics. By leveraging Samsung Electronics' AI and IT technologies, Element expects to further improve the accuracy of DNA sequencing and reduce costs, thereby generating a variety of business synergies in the field of precision medicine.

Tae Moon Roh, President and CEO (Head of DX Division) at Samsung Electronics, stated, "The combination of Samsung Electronics' expertise in AI, medical devices, and digital health with Element's innovative genome analysis technology will create synergies for the future of personalized medicine," adding, "Samsung Electronics will continue to invest broadly, from precision medical devices to digital health, with the goal of enhancing people's health."

Meanwhile, the expansion of this investment is not expected to result in any changes to management control at Element.

Yonhap News Agency

This content was produced with the assistance of AI translation services.